Unlocking Cancer Immunity: The SLAMF6 Breakthrough
Researchers have identified a previously unknown mechanism that allows tumors to evade the immune system: the SLAMF6 molecule. According to a study published in the journal Nature, this molecule acts as an internal “brake” on T cells, preventing them from effectively attacking cancer. Led by Dr. André Veillette of the Montreal Clinical Research Institute (IRCM) and the Université de Montréal, the team successfully developed monoclonal antibodies to block SLAMF6, showing promising results in shrinking tumors in laboratory mice.
How Does SLAMF6 Silence the Immune System?
Most known immune checkpoints require interaction with tumor cells to dampen the body’s defenses. SLAMF6 functions differently because it can activate itself directly on the surface of T cells. According to the research team, this self-activation triggers a cascade of signals that hinder the immune response in three distinct ways:
- It reduces the ability of T cells to infiltrate and attack cancer cells.
- It hinders the production of durable, long-lasting T cells.
- It accelerates immune exhaustion, where T cells lose their functional capacity to fight disease.
While current therapies like PD1 and PDL1 inhibitors focus on removing inhibitory signals coming from tumors, the SLAMF6 discovery addresses a “hidden” internal brake located directly on the immune cells themselves.
Can New Antibodies Outperform Existing Therapies?
The research team, directed by Dr. Veillette, developed monoclonal antibodies specifically designed to stop SLAMF6 from triggering its suppressive signals. In laboratory testing, these antibodies demonstrated significant advantages over existing approaches. The findings showed an increase in the activation of human T cells, a greater number of durable immune cells, and a measurable reduction in exhausted T cells.
Dr. Jean-François Côté, president and scientific director of the IRCM, noted that this discovery provides an innovative solution to the limitations of current treatments, particularly for patients who have developed resistance to standard immunotherapies. The study, titled “SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer,” suggests these antibodies could eventually serve as a standalone treatment or be combined with other immune-stimulating therapies.
What Are the Next Steps for Clinical Application?
The transition from laboratory success to patient care is the current priority. The research team is moving toward early-stage clinical trials to evaluate the safety and efficacy of these antibodies in humans. The focus will be on patients with solid tumors and blood cancers who no longer respond to PD1 or PDL1 inhibitors.
This research was supported by a coalition of organizations, including the Canadian Institutes of Health Research (CIHR), the Terry Fox Research Institute, BioCanRx, the Canadian Foundation for Innovation, and Québec’s Ministry of Economy, Innovation and Energy.
Frequently Asked Questions
What is SLAMF6?
SLAMF6 is a molecule found on the surface of T cells that acts as an “internal brake,” suppressing the immune system’s ability to fight cancer.
How do the new antibodies work?
The antibodies block SLAMF6 from binding to itself, effectively releasing the “brake” and allowing T cells to remain active and durable against tumors.
Who led this study?
The study was led by Dr. André Veillette, a medical professor at the Université de Montréal and director of the Molecular Oncology Research Unit at the IRCM.
Are you interested in the latest advancements in oncology? Subscribe to our research newsletter for updates on upcoming clinical trials and breakthrough therapies in immunotherapy.
